Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Genomics Policy: Data Will Be Used In Reviews Only By Sponsor Consent

Executive Summary

FDA will leave the decision to use a therapeutic product's pharmacogenomic data in regulatory submissions to the sponsor and an FDA review group

You may also be interested in...



Biomarkers, Communications Are Key To Accelerating R&D, FDA Says

Genentech's Herceptin is a good example of how the tradeoffs in targeted drug development can work out medically and commercially, FDA Commissioner McClellan told an IBC meeting in Boston Aug. 12

Biomarkers, Communications Are Key To Accelerating R&D, FDA Says

Genentech's Herceptin is a good example of how the tradeoffs in targeted drug development can work out medically and commercially, FDA Commissioner McClellan told an IBC meeting in Boston Aug. 12

Pharmacogenomic Data “Regulatory Impact” To Be Outlined In Guidance

The regulatory impact of different categories of pharmacogenomic data will be addressed in a draft guidance, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said at FDA's Science Board Advisory Committee meeting April 9

Related Content

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel